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BACKGROUND: Gastric cancer cells frequently metastasise, partly because of their highly invasive nature. Transforming growth factor-b
(TGF-b) receptor signalling is closely associated with the invasion of cancer cells. The aim of this study was to clarify the effect of a
TGF-b receptor (TbR) phosphorylation inhibitor on the invasiveness of gastric cancer cells.
METHODS: Four gastric cancer cell lines, including two scirrhous-type cell lines and two non-scirrhous-type cell lines, were used. A TbR
type I (TbR-I) kinase inhibitor, Ki26894, inhibits the phosphorylation of Smad2 at an ATP-binding site of TbR-I. We investigated the
expression levels of TbR and phospho-Smad2, and the effects of TGF-b in the presence or absence of Ki26894 on Smad2
phosphorylation, invasion, migration, epithelial-to-mesenchymal transition (EMT), Ras homologue gene family member A (RhoA),
ZO-2, myosin, and E-cadherin expression of gastric cancer cells.
RESULTS:T bR-I, TbR-II, and phospho-Smad2 expressions were found in scirrhous gastric cancer cells, but not in non-scirrhous gastric
cancer cells. Ki26894 decreased Smad2 phosphorylation induced by TGF-b1 in scirrhous gastric cancer cells. Transforming growth
factor-b1 upregulated the invasion, migration, and EMT ability of scirrhous gastric cancer cells. Transforming growth factor-b1
significantly upregulated the activity of RhoA and myosin phosphorylation, whereas TGF-b1 decreased ZO-2 and E-cadherin
expression in scirrhous gastric cancer cells. Interestingly, Ki26894 inhibited these characteristics in scirrhous gastric cancer cells.
In contrast, non-scirrhous gastric cancer cells were not affected by TGF-b1 or Ki26894 treatment.
CONCLUSION:AT bR-I kinase inhibitor decreases the invasiveness and EMT of scirrhous gastric cancer cells. Ki26894 is therefore
considered to be a promising therapeutic compound for the metastasis of scirrhous gastric carcinoma.
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There are two types of gastric cancer: diffuse type and intestinal
type, according to the Laure ´n classification (Lauren, 1965).
Scirrhous gastric carcinoma, also called diffuse-type gastric
carcinoma, or linitis plastica, is characterised by a diffusely
infiltrating growth accompanied by extensive stromal fibrosis and
a high frequency of metastasis to the lymph nodes and the
peritoneum (Yokota et al, 1999; Nakazawa et al, 2003), resulting in
an extremely poor prognosis (Otsuji et al, 2004; Kunisaki et al,
2005). The high invasive ability of cancer cells is responsible for
the diffusely infiltrating growth and frequent metastatic spread of
scirrhous gastric carcinoma.
Transforming growth factor-b (TGF-b) signals have an
important role in the metastatic spread of cancer cells (Saito
et al, 2000; Massague, 2008; Yang and Moses, 2008), such as
migration, invasion, and epithelial-to-mesenchymal transition
(EMT) (Thiery, 2002; Massague, 2008). Overexpression of TGF-b
is reported to be correlated with poor prognosis of gastric tumours
(Saito et al, 2000), especially scirrhous gastric carcinoma
(Kinugasa et al, 1998), suggesting that TGF-b signalling might
have an important role in the progression of scirrhous gastric
cancer cells (Inoue et al, 1997; Kinugasa et al, 1998; Kawajiri et al,
2008). Therefore, inhibition of TGF-b signalling in scirrhous
gastric carcinoma may yield beneficial effects through inhibition of
invasion and metastasis of cancer. Although there are several
reports of molecular target therapies against TGF-b signalling from
the viewpoint of adhesion (Kano et al, 2007; Kawajiri et al, 2008),
proliferation (Tateishi et al, 2000; Komuro et al, 2009), or
angiogenesis (Kano et al, 2007; Kawajiri et al, 2008) in scirrhous
gastric carcinoma, the effectiveness of TGF-b signalling inhibitor
on invasion and migration has not been proposed in this type
of carcinoma. Transforming growth factor-b activates TGF-b
receptor type II (TbR-II), which phosphorylates TGF-b receptor
type I (TbR-I) (Heldin et al, 1997; Massague, 2008). Activated TbR-
I kinase phosphorylates Smad2/3, which are associated with Smad4
and translocation in the nucleas as transcriptional factors (Heldin
et al, 1997; Massague, 2008). In this study, we investigated the
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gastric cancer.
MATERIALS AND METHODS
Compounds
A small synthetic molecule that interrupts the phosphorylation of
Smad2/Smad3 by TbR-I, namely, Ki26894, was synthesised by
Kirin Brewery Company (Gunma, Japan) as previously reported
(Ehata et al, 2007). Ki26894 was dissolved in PBS (Nikken Bio.,
Kyoto, Japan), stored at 41C, and used within 5 days. Transforming
growth factor-b1 was purchased from R&D Systems (Minneapolis,
MN, USA).
Cell lines
OCUM-2MLN (Fujihara et al, 1999) and OCUM-12 (Qiu et al,
2009) were derived from scirrhous gastric carcinomas. MKN-45
(Motoyama et al, 1986) and MKN-74 (Motoyama et al, 1986) were
derived from non-scirrhous gastric carcinomas. The culture
medium consisted of DMEM (Nikken Bio.) with the addition of
10% heat-inactivated fetal bovine serum (FBS; Equitech-Bio,
Kerrville, TX, USA), 100IUml
 1 penicillin (ICN Biomedicals,
Costa Mesa, CA, USA), 100mgml
 1 streptomycin (ICN Biomedicals),
and 0.5mM sodium pyruvate (Cambrex, Walkersville, MD, USA).
Cells were cultured at 371C in a humidified atmosphere containing
5% CO2 in the air.
Morphological findings
Cancer cells were also cultured with TGF-b1 (10ngml
 1) and/or
Ki26894 (0.1, 0.3, 1, 3, or 10mM). Cell morphology was observed
microscopically, 24, 48, and 72h after addition.
Wound healing assay
In vitro wound healing ability was measured by the method
described in the study by Borensztajn et al (2008), with some
modifications. Gastric cancer cells were cultured in six-well plates.
After the cells reached semi-confluence, a wound was created in
the cell monolayer using a pipette tip. Cancer cells were cultured
in serum-free DMEM, along with TGF-b1 (10ngml
 1) and/or
Ki26894 (10mM). Four scratched fields were randomly chosen and
the number of cell migrations was counted from pictures 24h after
treatment.
Invasion assay
In vitro invasiveness was measured by the method described in the
study by Albini et al (1987), with some modifications. We used
chemotaxis chambers with a 12mm-pore membrane filter (Kubota,
Osaka, Japan) coated with 50mg of matrigel in a 24-well culture
plate. Gastric cancer cells (2 10
3 cells per chamber) were seeded,
and TGF-b1 (a final concentration of 0 or 10ngml
 1) and/or
Ki26894 (a final concentration of 0, 0.1, 1, or 10mM) were added to
the upper chambers. After 72h incubation, cells that had not
moved to the lower wells were removed from the upper face of the
filters using cotton swabs, and the cells that had moved to the
lower surface of the filter were stained with haematoxylin. Cancer
cells that invaded through a filter coated with matrigel to the lower
surface of the membrane were manually counted under a
microscope at  200 magnification. The mean of six fields was
calculated as the sample value. The culture was performed in
triplicate.
Immunohistochemistry
BALB/c nude female mice, aged 4 weeks (Nihon CLEA, Tokyo,
Japan), were used in the studies. All experiments were performed
according to the standard guidelines for animal experiments of
Osaka City University Medical School. The expression of TbR-I,
TbR-II, and phosphorylated Smad2 of xenografts was examined.
Xenografts were established by injecting each cell (1 10
7) into the
flanks of nude mice. Four weeks after inoculation, mice were
killed, and the xenografted tumours were washed in PBS and fixed
in 10% formalin for paraffin sectioning. Immunohistochemical
determination of TbR-I, TbR-II, and phosphorylated Smad2 was
carried out according to the manufacturer’s instructions. In brief,
slides were deparaffinised, and were heated for 10min at 1051C
by autoclave in Target Retrieval Solution (Dako, Carpinteria, CA,
USA). The sections were then incubated with 3% hydrogen
peroxide to block endogenous peroxidase activity. The specimens
were incubated with anti-TbR-I antibody (Lab vision, Fremont,
CA, USA; 1:100), anti-TbR-II antibody (Lab vision; 1:100),
and anti-phospho-Smad2 antibody (Chemicon International,
Themecula, CA, USA; 1:2000) overnight at 41C. The sections were
incubated with biotinylated goat anti-rabbit immunoglobulin G for
30min. The slides were treated with streptavidin-peroxidase
reagent, and were incubated in PBS diaminobenzidine and 1%
hydrogen peroxide v/v, followed by counterstaining with Mayer’s
haematoxylin.
Western blot analysis
The inhibition by Ki26894 of the phosphorylation of Smad2 and its
migration ability in gastric cancer cells were examined by western
blotting. Briefly, cell lines were cultured in DMEM with 2% FBS for
2 days. The culture was rinsed with PBS and incubated in serum-
free DMEM with reagent (TGF-b1: a final concentration of 0 or
10ngml
 1; Ki26894: a final concentration of 0, 0.1, 0.3, 1, 3, or
10mM) for 60min. The cells were lysed in a lysis buffer. Aliquots
containing 30mg of total protein were subjected to SDS–PAGE,
and the protein bands were transferred to a polyvinylidene
difluoride membrane (Amersham, Aylesbury, UK). The membrane
was kept in TBS-T (10mM TBS and 0.05% Tween 20) supplemen-
ted with 5% non-fat milk or 5% bovine albumin (Sigma, St Louis,
MO, USA) at room temperature for 1h. Next, the membrane was
placed in a TBS-T solution containing each primary antibody. The
membrane was placed in TBS-T solution containing the primary
antibody, phospho-Smad2 (Cell Signaling Tec, Danvers, CO, USA,
Ser 465/467; 1:1000), Smad2/3 (Cell Signaling Tec; 1:1000), ZO-2
(Cell Signaling Tec; 1:1000), phospho-myosin light chain-2 (Cell
Signaling Tec, Thr18/Ser19; 1:1000), E-cadherin (Cell Signaling
Tec; 1:1000), or b-actin (Cell Signaling Tec; 1:1000), and allowed
to react at 41C overnight for western blotting. Next, each antibody
was washed three times with TBS-T for 10min, and a peroxidase-
labelled secondary antibody (Amersham) reactive with the primary
antibody was added. The membrane was placed in the TBS-T
solution, kept at room temperature for 1h, and then washed.
Bands were detected using an enhanced chemiluminescence
system (Amersham). An immunoblot analysis was performed
twice. PANC-1, a pancreas cancer cell line, was used as the positive
control of Smad2 (Romero et al, 2008; Horiguchi et al, 2009).
Ras homologue gene family member A activation assay
Activated Ras homologue gene family member A (RhoA) proteins
were measured with a RhoA activation G-LISA (Absorbance
Based) assay kit (Cytoskeleton, Denver, CO, USA) according to the
manufacturer’s instructions. The activation of RhoA by TGF-b1
and the inhibition by Ki26894 in gastric cancer cells were
examined as follows. Cell lines were cultured in DMEM with 2%
FBS. The culture was rinsed with PBS and incubated in serum-free
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10ngml
 1; Ki26894: a final concentration of 0 or 10mM)
for 10min. Activation of RhoA analysis was performed for the
third time.
Statistical analysis
Comparisons among data sets were made with the Kruskal–Wallis
one-way ANOVA by ranks, followed by Dunn’s multiple compar-
ison test. A difference was considered significant when the P-value
was 0.05 or less.
RESULTS
Expression of TbR-I, TbR-II, and phospho-Smad2 in
gastric cancer cells
Figure 1A shows the expression level of TbR-I, TbR-II, and
phospho-Smad2 of gastric cancer cells in xenografted tumours.
TbR-I and TbR-II were immunolocalised at the membrane and
cytoplasm, respectively, of gastric cancer cells. High expression
levels of TbR-I and TbR-II were found in scirrhous gastric cancer
cells (OCUM-2MLN and OCUM-12), but not in non-scirrhous
gastric cancer cells (MKN-45 and MKN-74). Phospho-Smad2 was
expressed in the nucleus of scirrhous gastric cancer cells. The
overexpression of phospho-Smad2 was observed in scirrhous
gastric cancer cells, but not in non-scirrhous gastric cancer cells.
Effects of Ki26894 on Smad2 phosphorylation in gastric
cancer cells
To determine whether the small-molecule compound, Ki26894,
inhibits TGF-b signalling, the effect of Ki26894 on TGF-b-induced
Smad2 phosphorylation was examined in gastric cancer cells.
Smad2 phosphorylation was increased by TGF-b1 (10ngml
 1)
in scirrhous gastric cancer cell lines, OCUM-2MLN and OCUM-12.
Smad2 phosphorylation was decreased in a dose-dependent
manner by Ki26894 from 3 to 10mM. In contrast, Smad2
phosphorylation was not detected with TGF-b1 treatment in
non-scirrhous gastric cancer cell lines, MKN-45 and MKN-74
(Figure 1B, 1C).
Ki26894 reduces the migration of scirrhous gastric cancer
cells induced by TGF-b
Figure 2A is a representative phase-contrast photograph of
OCUM-2MLN cells. The number of migrating OCUM-2MLN cells
was increased by TGF-b1 (10ngml
 1) and was decreased in the
presence of Ki26894 (10mM). The migrating ability of OCUM-12
cells was increased in the presence of TGF-b1 (Supplementary
Movie 1), compared with the control (Supplementary Movie 2).
Transforming growth factor-b1 significantly stimulated the
migration of OCUM-2MLN (Po0.001) and OCUM-12 cells
(P¼0.004). Ki26894 significantly inhibited the migration-stimu-
lating ability of TGF-b1 in both OCUM-2MLN (Po0.001) and
OCUM-12 cells (P¼0.006). In contrast, neither TGFb1 nor
Ki26894 affected migration by the non-scirrhous gastric cancer
cell lines used (Figure 2B).
Effect of Ki26894 on scirrhous gastric cancer cell invasion
Figure 3A is a representative phase-contrast photograph of
OCUM-12 cells that have invaded into a 12-mm-pore membrane
filter. The number of OCUM-12 cells displaying EMT was
significantly increased in the presence of TGF-b1 when compared
with the control. The migration-stimulating activity of TGF-b1 was
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Figure 1 Expression of TGF-b signalling and inhibitory effect of Ki26894. (A) Expression level of TGF-b receptor and phospho-Smad2. The
overexpression of TGF-b receptor type I (TbR-I), type II (TbR-II), and phospho-Smad2 (P-Smad2) was observed in scirrhous gastric cancer cell lines,
OCUM-2MLN and OCUM-12, but not in non-scirrhous gastric cancer cell lines, MKN-45 and MKN-74. (B, C) Effects of Ki26894 on TGF-b-induced Smad2
phosphorylation of gastric cancer cells. PANC-1 was used as positive control of Smad2 phosphorylation. Transforming growth factor-b stimulated Smad2
phosphorylation in PANC-1, OCUM-2MLN, and OCUM-12 cells. Total Smad2/3 expression was recognised in all four gastric cancer cell lines and no
difference in expression level was found on addition of TGF-b1 or Ki26894. Transforming growth factor-b1 (10ngml
 1) stimulated Smad2 phosphorylation
in both scirrhous gastric cancer cell lines, but not in non-scirrhous cancer cell lines, MKN-45 and MKN-74. Smad2 phosphorylation was decreased in a dose-
dependent manner by Ki26894 in scirrhous gastric cancer cell lines. PANC-1, a pancreas cancer cell line, was used as positive control of Smad2.
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growth factor-b1 (10ngml
 1) significantly stimulated invasion
(Po0.001) by scirrhous gastric cancer cell lines, but not by non-
scirrhous gastric cancer cell lines. Ki26894 (10mM) significantly
(Po0.001) inhibited invasion by scirrhous gastric cancer cells. In
contrast, invasion was not affected by TGF-b1 or Ki26894 in the
non-scirrhous gastric cancer cell lines used (Figure 3B).
Effects of TGF-b1 and Ki26894 on the morphological
characteristics of gastric cancer cells
Epithelial-to-mesenchymal transition was found in both scirrhous
gastric cancer cell lines (OCUM-12 and OCUM-2MLN) in culture
with the addition of TGF-b1. An increase in the number of
attached and spreading cells was found after the addition of
TGF-b1, whereas most of the OCUM-2MLN and OCUM-12 cells
without TGF-b1 treatment were still round. OCUM-12 cells
exhibited loss of cell–cell adhesion and spindle-shaped cells.
However, Ki26894 (10mM) inhibited these morphological changes
associated with EMT in scirrhous gastric cancer cells. In contrast,
non-scirrhous gastric cancer cell lines (MKN-45 and MKN-74)
did not display these morphological changes after the addition of
TGF-b1 (Figure 4).
Effects of Ki26894 on cellular signalling pathways
exhibited during migration
Transforming growth factor-b1 significantly upregulated the active
form of RhoA in scirrhous gastric cancer cell lines, OCUM-2MLN
(P¼0.008) and OCUM-12 (P¼0.007), when compared with
control. However, Ki26894 significantly inhibited the active
RhoA induced by TGF-b1 in scirrhous gastric cancer cell lines,
OCUM-2MLN (P¼0.047) and OCUM-12 (P¼0.029). In contrast,
active RhoA was not affected by TGF-b1 or Ki26894 in non-
scirrhous cancer cell lines (Figure 5A). Transforming growth
factor-b1 (10ngml
 1) decreased ZO-2 and E-cadherin expression
in scirrhous gastric cancer cells and increased myosin light chain-2
phosphorylation (p-myosin), but not in non-scirrhous gastric
cancer cells. In addition, Ki26894 increased ZO-2 and E-cadherin
expression and inhibited p-myosin in scirrhous gastric cancer cells
(Figure 5B).
DISCUSSION
In this study, scirrhous gastric cancer cells expressed TbR-I
and TbR-II. Furthermore, TGF-b stimulated the phosphorylation
of Smad2 in scirrhous gastric cancer cells as previously
reported (Komuro et al, 2009), but not in non-scirrhous
gastric cancer cells, suggesting that TGF-b signalling is
active in scirrhous gastric cancer, but not in non-scirrhous gastric
cancer.
Transforming growth factor-b1 stimulated EMT in scirrhous
gastric cancer cells, but not in non-scirrhous gastric cancer cells.
Epithelial-to-mesenchymal transition is characterised by spindle-
shaped cells with a reduction in epithelial cell markers of cell–cell
adhesion molecules (Thiery, 2002; Jung et al, 2006; Revenu and
Gilmour, 2009). The expression levels of cell–cell adhesion
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Figure 2 Effect of Ki26894 on the wound healing ability of cancer cells. (A) Representative pictures from three experiments are shown. The number of
OCUM-2MLN cells that migrated over the wound line (dotted line) was increased by TGF-b1 treatment when compared with that of control. The migrating
cells displayed spindle shapes characteristic of epithelial-to-mesenchymal transition (EMT). Ki26894 (10mM) downregulated the ability of OCUM-2MLN cells
to migrate over a wound line. (B) TGF-b1 significantly stimulated the migration of scirrhous gastric cancer cells, but not of non-scirrhous gastric cancer cells.
Ki26894 (10mM) significantly inhibited the migration of scirrhous gastric cancer cells.
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smolecules, ZO-2 and E-cadherin, were downregulated by
TGF-b1 in scirrhous gastric cancer cells. Moreover, TbR
signalling activates RhoA, which mediates the upregulation of
myosin light chain-2 phosphorylation (Shook and Keller, 2003;
Fan et al, 2007) and downregulation of cell–cell tight junctions
(Takaishi et al, 1997; Yamazaki et al, 2008). Transforming
growth factor-b1 significantly upregulated active RhoA and
phospho-myosin of scirrhous gastric cancer cells. The EMT of
scirrhous gastric cancer cells induced by TGFb signalling might
be mediated by the regulation of RhoA, myosin, ZO-2, and
E-cadherin. Scirrhous gastric carcinoma is a diffuse-type
gastric cancer characterised by loss of cell–cell adhesion.
Transforming growth factor-b signalling of downregulation of
cell–cell adhesion might be closely associated with the histologen-
esis of scirrhous gastric carcinoma. Intestinal-type tumours show
an expanding growth with definite border according to the Laure ´n
classification (Lauren, 1965). These histological differences
between diffuse-type and intestinal-type tumours might be
determined in part by the response of gastric cancer cells to
TGFb/TbR signalling.
Transforming growth factor-bR signalling increased the migra-
ting ability of scirrhous gastric cancer cells, but not of non-
scirrhous gastric cancer cells. Transforming growth factor-b1
activates RhoA, which promotes cancer cell invasion and
eventually leads to metastasis by disrupting E-cadherin-mediated
adherens junctions (Chang et al, 2009). In this study, TGF-b1
significantly upregulated active RhoA of scirrhous gastric
cancer cells. Ras homologue gene family member A might regulate
not only EMT but also migrating ability in scirrhous gastric
cancer cells through TGFb signalling. High migration ability
of scirrhous-type cancer cells by TGFb signalling is one of the
reasons responsible for a diffusely infiltrating growth with an
indistinct border from the surrounding tissue. Scirrhous carcinomas
carry a worse prognosis than other types of gastric carcinomas,
reflecting a high frequency of metastasis (Otsuji et al, 2004;
Ikeguchi et al, 2009). Previous studies have reported that the
phenotypes of metastatic cancer cells are associated with migration
ability (Jung et al, 2006; Revenu and Gilmour, 2009). The different
response in TGF-b/TbR signalling between scirrhous types and
non-scirrhous types might explain the poorer prognosis of
scirrhous-type gastric cancers compared with non-scirrhous-types
of gastric cancers.
Transforming growth factor-b is produced not only by scirrhous
gastric cancer cells (Yoshida et al, 1989; Niki et al, 2000) but also
by cancer-associated fibroblasts (Mizoi et al, 1993; Inoue et al,
1997; Zeisberg et al, 2007). Our preliminary study recognised that
both scirrhous gastric cancer cell lines and gastric fibroblasts
produced TGF-b (Yashiro et al, 1996b; Inoue et al, 1997). These
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Figure 3 Ki26894 inhibits invasion by scirrhous gastric cancer cells. (A) Representative pictures of invading gastric cancer cells. OCUM-12 cells invaded
into a 12mm-pore membrane filter in the presence of TGF-b1 when compared with control. Most of the invaded cells show epithelial-to-mesenchymal
transition (arrow heads). Ki26894 (10mM) inhibited the invasion induced by TGF-b1. (B) Transforming growth factor-b1 significantly stimulated the invasive
behaviour of OCUM-2MLN and OCUM-12 cells. Ki26894 (10mM) significantly inhibited the invasion seen in these cells. In contrast, invasion by non-scirrhous
gastric cancer cell lines, MKN-45 and MKN-74, was not affected by TGF-b1 or by Ki26894.
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sfindings suggest that the invasive capacity induced by TGF-b
may be influenced in both an autocrine and paracrine
manner. Tumour cells in scirrhous carcinoma produce more
TGFb, which is a key mediator of fibroblast activation, than
those in non-scirrhous carcinoma (Yoshida et al, 1989; Mahara
et al, 1994). Scirrhous gastric carcinoma is characterised by cancer
cell infiltration accompanied by extensive stromal fibrosis
(Yashiro et al, 1996a). The typical histological findings of rapid
infiltration with fibrosis might indicate that the surrounding
stromal fibroblasts contribute to cancer progression more
intensely in scirrhous gastric cancer than in non-scirrhous gastric
cancer.
Specific small molecules designed to inhibit the effects of
TGF-b at the level of signalling receptors may be a promising
strategy for patients with advanced gastric carcinoma. In this
study, a TbR-I inhibitor, Ki26894, displayed inhibitory activity
against phosphorylation of Smad2 in scirrhous gastric cancer,
suggesting that the small-molecule compound Ki26894 is a
potent TbR kinase inhibitor. Migration and invasion stimulated
by TGF-b were significantly inhibited by Ki26894 in scirrhous
gastric cancer cells. In contrast, the migration and invasion by
non-scirrhous cancer cells were not affected by TGF-b1o rb y
Ki26894. Cell motility and invasion are critical metastatic
events in cancer progression (Ehata et al, 2007). Ki26894, a small
molecule designed to inhibit TbR, might be a promising
therapeutic agent for antagonising the metastatic phenotypes seen
through autocrine TGF-b/TbR signalling in scirrhous gastric
cancer. We previously reported that the TbR inhibitor, A-77,
decreased the expression of integrins in cancer cells, which
resulted in a decreased adhesion of scirrhous gastric cancer
cells to peritoneum (Kawajiri et al, 2008). Furthermore,
Ki26894 inhibited the upregulation of active RhoA and phospho-
myosin and inhibited the downregulation of E-cadherin and
ZO-2 expression in scirrhous gastric cancer cells. Invasion by
scirrhous gastric cancer cells may be inhibited by a TbR
inhibitor through regulation of RhoA, myosin, E-cadherin, and
ZO-2 expression. These findings suggested that inhibition
of the biological effects of TGF-b might affect the adhesion,
migration, and invasion of cancer cells and may be an attractive
strategy for prevention of distant metastasis by scirrhous
gastric cancers.
In conclusion, TGFb signalling stimulated the EMT and
invasion ability of scirrhous gastric cancer cells through
regulation of RhoA, myosin, ZO-2, and E-cadherin. Ki26894,
which inhibits TbR-I phosphorylation, significantly inhibited
invasion by scirrhous gastric cancer cells. The TbR might be a
promising target molecule for the treatment of scirrhous gastric
carcinoma.
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Figure 4 Effects of TGF-b1 and Ki26894 on morphological characteristics of gastric cancer cells. Epithelial-to-mesenchymal transition (arrow heads) by
TGF-b1 (10ngml
 1) was shown in scirrhous gastric cancer cell lines, OCUM-2MLN and OCUM-12, but not in non-scirrhous gastric cancer cell lines,
MKN-45 and MKN-74. Pseudopod formation was remarkable in OCUM-12 cells in the presence of TGF-b1. Epithelial-to-mesenchymal transition by
TGF-b1 in scirrhous gastric cancer cells was inhibited by Ki26894 (10mM).
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